Our top pick for
Building a portfolio
BioCryst Pharmaceuticals, Inc is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioCryst Pharmaceuticals employs 246 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$2.75 - $14.24|
|50-day moving average||$11.24|
|200-day moving average||$7.74|
|Wall St. target price||$14.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.15|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$17.8 million|
|Gross profit TTM||$-106,828,000|
|Return on assets TTM||-42.83%|
|Return on equity TTM||-1925.37%|
|Market capitalisation||$2 billion|
TTM: trailing 12 months
There are currently 23.3 million BioCryst Pharmaceuticals shares held short by investors – that's known as BioCryst Pharmaceuticals's "short interest". This figure is 12.5% down from 26.7 million last month.
There are a few different ways that this level of interest in shorting BioCryst Pharmaceuticals shares can be evaluated.
BioCryst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of BioCryst Pharmaceuticals shares currently shorted divided by the average quantity of BioCryst Pharmaceuticals shares traded daily (recently around 7.3 million). BioCryst Pharmaceuticals's SIR currently stands at 3.22. In other words for every 100,000 BioCryst Pharmaceuticals shares traded daily on the market, roughly 3220 shares are currently held short.
However BioCryst Pharmaceuticals's short interest can also be evaluated against the total number of BioCryst Pharmaceuticals shares, or, against the total number of tradable BioCryst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCryst Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 BioCryst Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1413% of the tradable shares (for every 100,000 tradable BioCryst Pharmaceuticals shares, roughly 141 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioCryst Pharmaceuticals.
Find out more about how you can short BioCryst Pharmaceuticals stock.
We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $2.75 up to $14.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.6531. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.